甲氨蝶呤治疗急性淋巴细胞白血病的疗效及对患者BAFF、APRIL的影响

目的:探讨甲氨蝶呤治疗急性淋巴细胞白血病的疗效及对患者B淋巴细胞刺激因子(BAFF)、增殖诱导配体(APRIL)的影响。方法:选择2016年8月至2018年9月我院收治的急性淋巴细胞白血病患者50例进行研究,以随机数表法分为观察组(n=26)和对照组(n=24)。对照组给予化疗治疗,观察组采用甲氨蝶呤治疗。比较两组患者的临床疗效、BAFF、APRIL、CD4~+、CD8~+、CD4~+/CD8~+水平变化情况及不良反应发生情况。结果:治疗后,观察组总有效率84.62%显著高于对照58.33%,差异显著(P0.05);治疗前,两组BAFF、APRIL水平无显著差异(P0.05);治疗后,两组BAFF、APRIL水平均显著下降,且观察组低于对照组(P0.05);治疗前,两组T淋巴细胞亚群水平无显著差异(P0.05);治疗后,两组T淋巴细胞亚群水平均显著改善,且观察组CD4~+、CD4~+/CD8~+高于对照组,CD8~+低于对照组(P0.05);两组患者不良反应发生情况均无统计学意义(P0.05)。结论:在急性淋巴细胞白血病患者中应用甲氨蝶呤效果显著,可有效改善患者BAFF、APRIL水平。

Curative efficacy of methotrexate in treatment of Acute Lymphocytic Leukemia and Its Effectson Patients' BAFF and APRIL

ABSTRACT Objective: To study Curative efficacy of methotrexate in treatment of Acute lymphocytic leukemiaand its effectson patients'' B lymphocyte stimulating factor (BAFF), proliferation-induced ligand (APRIL). Methods: 50 patients with acute lymphoblastic leukemia admitted to our hospital from August 2016 to September 2018 were selected for the study, were divided into observation group (n=52) and control group (n=48) by random number table method. The control group was treated with chemotherapy and the observation group was treated with methotrexate on the basis of the control group. The clinical efficacy, BAFF, APRIL, CD4⁺, CD8⁺, CD4⁺/CD8⁺ levels and adverse reactions of patients in the two groups were compared. Results: After treatment, the total effective rate of 84.62% in the observation group was significantly higher than that in the control group 58.33%, with a significant difference (P < 0.05). Before treatment, there was no significant difference in BAFF and APRIL levels between the two groups (P>0.05). After treatment, BAFF and APRIL levels in both groups decreased significantly, and the observation group was lower than the control group (P<0.05). Before treatment, there was no significant difference in T lymphocyte subsets between the two groups (P>0.05). After treatment, T lymphocyte subsets in both groups were significantly improved, and CD4⁺, CD4⁺/CD8⁺ in the observation group were higher than those in the control group, while CD8⁺ was lower than those in the control group (P<0.05). The incidence of adverse reactions in the two groups was not statistically significant (P>0.05). Conclusion: Methotrexate has a significant effect in patients with acute lymphoblastic leukemia, and can effectively improve the BAFF and APRIL levels of patients.